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Serum MMP-9 increases statistically signiﬁcantly ( p < 0.001) with
the increase of the severity of the stenosis and the number of the
affected arteries: no severe stenosis (<75% stenosis) (0.245
 0.086 ng/ml); 1 vessel severe (>75%) stenosis (0.317  0.132 ng/
ml), 2 vessel severe stenosis (0.348  0.157 ng/ml), 3 vessel severe
stenosis (0.422  0.112 ng/ml).
Furthermore, serum MMP-9 enzyme increases with accordance of
severity of the myocardium injury with the statistical signiﬁcance
( p < 0.01): the borderline abnormality group (CIIS < 10, 0.227
 0.099 ng/ml), possible injury (CIIS 10–15, 0.317  0.132 ng/ml),
probable injury (CIIS > 15, 0.376  0.132 ng/ml) group. MMP-9
levels were signiﬁcantly higher in the probable injury (CIIS >15)
patients compared to the possible injury (CIIS 10–15) patients
( p < 0.001).
Conclusion: An increase in serum MMP-9 enzyme levels is a risk
factor of the coronary atherosclerotic plaque rupture (OR = 0.001,
p < 0.001).
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Background:Cardiovascular disease (CVD) is an important cause of
mortality andmorbidity in India. Mortality statistics andmorbidity
surveys indicate substantial regional variations in CVD prevalence
and mortality rates. WHO has predicted that from years 2000 to
2020 disability-adjusted life years lost from coronary heart disease
in India shall double in both men and women from 7.7 and 5.5
million, respectively. This health scenario will therefore demand a
robust healthcare infrastructure and integrated approach of CVD
prevention and management.
Aim: To study impact on patient & procedure outcomes of Cath lab
by monitoring of Cath lab quality indicators.
Objectives: (a) Tomaintain a dedicated database of Cath lab quality
indicators (CQI) as a continuous improvement initiative. (b) Bench-
marking Cath lab procedural outcomes against current standards
of Cath lab quality for future improvisation.
Methodology: This study was carried out from February 2013 to
February 2015& involved 2000 cases. 3 duration groups of 8months
eachwere consideredwith 650, 800, 550 patients in 1st eightmonth
group, 800 patients in 2nd eight month group & 550 patients in 3rd
eight month group respectively.
Inclusion criteria: Patients above 18 years of age, admitted for diag-
nostic coronary angiograms and/or PCI procedures who have given
written informed consent for above procedures.
Exclusion criteria: Post-operative CABG patients, Patients studied for
non-coronary issues, such as pulmonary hypertension, cardio-
myopathy, valvular disease, or adult congenital heart disease
who did not undergo PCI.
Data collection technique & tools: Documentation of Cath lab quality
indicatorswasdoneonbasisofGUIDELINESas laiddownby ‘‘Quality
Assessment and Improvement in Interventional Cardiology: 2011
Statement of the Society of Cardiovascular Angiography and Inter-
vention (SCAI) & 2012 ACCF & SCAI Expert Consensus Document on
Cardiac Catheterization Laboratory Standards Update.
Salient results: (a) The mean door-to-balloon time (DTB) improved
signiﬁcantly from 84 min in 1st group to 79 min in 2nd group to
73 min in last group. The average DTB in all the 3 groups were
found to be well within the recommended timeframe of 90 min as
per AHA guidelines.
(b) For the patients who underwent elective PCI or PAMI, 75.2% of
the procedures done were appropriately indicated as per the
appropriate use criteria of AHA. 23.5% of the PCI procedures were
moderately appropriate & only 1.3% of the procedures performed
had rarely appropriate indications. Also a positive trend was noted
for use of appropriate indications from 1st group towards the last
group. On the other hand, use of rarely appropriate indication for
PCI showed statistically signiﬁcant decline from 1.6% to 1.3% to
1.1% from 1st to 3rd group respectively; reﬂecting the trend
towards guideline-based practice.
(c) Access site complications showed a declining trend with 26 com-
plications in1stgroup, 10complications in2ndgroup&4 in lastgroup.
(d) Amongst other vascular complications, a total, 0.2% of abrupt
coronary vessel closurewith slowﬂow, 0.4% coronary perforations,
0.8% coronary dissections, 0.5% cardiac tamponade were noted
with declining trend from 1st group to 3rd group.
(e) Re-infarctions were noted as 0.3% on-table, 1% during hospital
stay. Only 1 case of subacute stent thrombosis was seen & no cases
requiring emergency CABG were seen during study period. There
were 0.3% (5) cases of pulmonary edema, 0.2% (4) cases of stroke
but none of them observed in 3rd eight month group. Morbidity
owing to above complications in our study is well within the
standard reported data.
(f)Overall incidenceofdeathwasnoted as (0.00%)on table, (0.10%) in
hospital & (0.05%) after 30 dayswith all of these events encountered
in primary PCI (PAMI) cases while the survival rate was overall
99.85%. Considering the American heart association guidelines on
mortality to be below 1% for CAG <2% for PTCA, <5% for PAMI,
observations in above study are in accordance with the guidelines.
(g) The use of mean contrast volume & Radiation was in accor-
dance with the ‘‘ALARA’’ principle (as low as reasonably achiev-
able) of AHA and the recent SIR (Society of Interventional
Radiology) guidelines reﬂecting institutional trend towards prac-
tising safety standards for Radiation.
Conclusions: This study has allowed collection of data pertaining
2000 patients undergoing coronary angiography and/or angio-
plasty, analysis of their demographic, epidemiologic, clinical vari-
ables with comparison amongst 3 duration-based groups & also
contemporary international studies & the ACC/AHA guidelines
revealing mortality & morbidity parameters as well within the
framework of standard guidelines. It thus reﬂects upon use of
standard practices in Interventional cardiovascular care, culmi-
nating into favorable patient outcomes. The study has shown a
positive impact on patient & procedure outcomes bymonitoring of
Cath lab quality indicators. It has helped establish a continuous
care initiative in Cath lab by maintaining a dedicated database of
Cath lab quality indicators allowing for future benchmarking of
procedural outcomes against standard practices in cardiovascular
care thus achieving all aims and objectives it had set out with. The
study emphatically recommends monitoring of Cath lab quality
indicators as a routine practice in Cath labs everywhere. Inputs
from cardiac catheterization laboratories from all around our
country into a common National Registry will go a long way in
assessing current trends in patient presentation, patient manage-
ment, improve patient outcomes, also help modulate cardiovas-
cular guidelines as per national scenario, aid in formulating newer
benchmarks and probably contribute to the next wave of evolution
in Interventional cardiology.
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Background: Thrombolysis in ST elevationMI (STEMI) continues to
be life savingmeans of reperfusion therapy in our country specially
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when primary PCI is not possible within recommended door to
balloon time. Our objective was to conclude the efﬁcacy and safety
of tenecteplase in patients with STEMI.
Method: Data of 500 patients with STEMI who received tenecte-
plase in the last 1 year were analyzed.
Result: 90% patients had successful thrombolysis (SUCC.TH).
Hypertensives, diabetics, smokers and dyslipidemic patients had
SUCC.TH rates comparable to the general patient data. SUCC.TH
rates were signiﬁcantly lower in the elderly patients (>70 years,
86%, p < 0.0001), patients with history of IHD (88%, p < 0.0004) and
in patients receiving tenecteplase >6 h after onset of chest pain
(80%, p < 0.0001). SUCC.THwas signiﬁcantly higher in patientswho
received early thrombolysis (<3 h after onset of chest pain, 89%,
p = 0.006). Overall mortality was 1.5%. It was signiﬁcantly higher in
the elderly (4.5%), patients with history of IHD (3%), females (3%),
with delayed thrombolysis (5%). Overall incidence of ICH 0.3%,
other bleeds 2%, stroke 0.1% and ventricular tachyarrhythmias
2.5%were noted. Age>70 years, diabetes, dyslipidemia and history
of IHD were associated with a higher incidence of heart failure, re
infarction or ventricular tachyarrhythmias. Incidence of ICH and
other bleeds were comparable amongst all patient subgroups.
Ventricular arrhythmias were signiﬁcantly higher in dyslipi-
demics, with history of IHD, Killip class III & IV.
Conclusion: The study conﬁrmed the safety and efﬁcacy of tenec-
teplase.
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Background: Diabetes has been an Achilles heel of patients with
limus eluting drug-eluting stents (DES). In SPIRIT sub studies PES
had equivalent or better results than EES in Insulin requiring
diabetics. Our objective was to analyze this factor in Tuxedo-India
study, the largest ever DES study in patients with diabetesmellitus
comparing PES with EES.
Method: TUXEDO is a prospective, randomized, multicentre clin-
ical trial in patients with DM comparing the safety and efﬁcacy
outcomes of a PES with EES in a non-inferiority trial design.
We randomly assigned 1830 patients with diabetes mellitus to
receive either PES (TAXUS ElementTM) or EES (XIENCE PrimeTM)
in a non-inferiority trial design. Of these patients, 747 (40%) were
insulin requiring diabetics; 365/914 (39.9%) in PES group and
382/916 (41.7%) in the EES group. In a subset analyses, we evaluated
the 1-year rates of target-vessel failure (TVF), myocardial infarc-
tion (MI), stent thrombosis (ST), target-lesion revascularization
(TLR), and target-vessel revascularization (TVR) with PES or EES
in insulin requiring diabetics.
Results: The baseline characteristics of PES and EES groups in
insulin requiring diabetics were comparable. In insulin requiring
patients, there was a statistically signiﬁcant higher 1-year rate of
TVF in the PES group as compared to the EES group (7.9% vs. 3.4%,
p = 0.006). In addition, the rate of MI (4.4% vs. 1.3%, p = 0.01), ST
(3.0% vs. 0.5%, p = 0.009), TLR (5.2% vs. 1.0%; p = 0.001) andTVR (5.2%
vs. 1.0%; p = 0.001) was signiﬁcantly higher in the PES group com-
pared to the EES group over 1-year follow-up period.
Conclusion: PES, as compared to EES had higher rates of TVF,
MI, ST, TVR, and TLR at 1-year follow-up. The superiority of
EES, as compared to PES was maintained in insulin requiring
diabetics.
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Background: Prior trials (such as the SPIRIT trials) have shown the
superiority of EES over PES in general cohort. However, subgroup
analyses from these trials have failed to consistently show a
superiority of EES over PES in the diabetic cohort, leading to the
general notion that a 'taxol' eluting stent (such as PES) works as
well as a limus eluting stent (such as EES) in subjects with DM. Our
objective was to conduct a sufﬁciently powered randomized trial
comparing the efﬁcacy and safety of PESwith EES in a population of
patients with DM on drug treatment.
Method: TUXEDO is a prospective, randomized, multicenter clin-
ical trial in patients with DM comparing the safety and efﬁcacy
outcomes of a PES with EES in a non-inferiority trial design.
We randomly assigned a total of 1830 patients with DM, at 46
centers in India to receive either PES (TAXUS ElementTM Boston
scientiﬁc) or EES (Xience PrimeTM Abbott Vascular) without a
routine angiographic follow up. The primary endpoint was target
vessel failure deﬁned as a composite of cardiac death, target vessel
myocardial infarction or ischemia driven target vessel revascular-
ization at 12 months follow up.
Results: The mean age of the patients included was 58.4 years,
males 75.3% with the mean duration of DM being 6.5 years. Insulin
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